Clinical Trial · NCT07934056

PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging

Overview

This study will evaluate the diagnostic performance and safety of gallium-68 (68Ga)-labeled dual-target imaging agents in patients with prostate cancer. These investigational agents are designed to target either EphA2 and prostate-specific membrane antigen (PSMA), or ACP3 and PSMA, for positron emission tomography/computed tomography (PET/CT) imaging. The main aims are to assess how well these imaging agents detect prostate cancer lesions, evaluate their safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore their potential use in early diagnosis, determining the extent of cancer spread, and detecting cancer recurrence.

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Early Phase 1

ClinicalTrials.gov

NCT07934056

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

  • Inability to tolerate or cooperate with PET/CT imaging, for example, due to claustrophobia.Severe, uncontrolled disease affecting vital organs, including the heart, liver, or kidneys.Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.